ArticleAnnals of internal medicine2021
In adults, the Oxford/AstraZeneca vaccine had 70% efficacy against COVID-19 >14 d after the 2nd dose.
Article in Annals of internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Article
- Challenges and Recent Advancements in COVID-19 Vaccines.Microorganisms · 2023Review
- Regulating the microenvironment with nanomaterials: Potential strategies to ameliorate COVID-19.Acta pharmaceutica Sinica. B · 2023Review
- Long COVID in the context of social determinants of health.Frontiers in public health · 2023Article
- Reduction in COVID-19 Vaccine Effectiveness against SARS-CoV-2 Variants in Seoul according to Age, Sex, and Symptoms: A Test-Negative Case-Control Study.International journal of environmental research and public health · 2022Article
- Local myofascitis of the deltoid muscle after administration of the AstraZeneca (AZD1222) COVID-19 vaccine: two cases, infectious and inflammatory.JSES reviews, reports, and techniques · 2022Article
- Incidence and severity of COVID-19 infection post-vaccination: a survey among Indian doctors.Infection · 2022Article
- Immunomodulation of COVID-19 severity by helminth co-infection: Implications for COVID-19 vaccine efficacy.Immunity, inflammation and disease · 2022Review
- Spectrum of neurological complications following COVID-19 vaccination.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Review
- Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets.Current neuropharmacology · 2022Article
- New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19.Multiple sclerosis and related disorders · 2022Article
- COVID-19 cross-sectional study in Maricá, Brazil: The impact of vaccination coverage on viral incidence.PloS one · 2022Article
- A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines.International immunopharmacology · 2021Review
- Could live attenuated vaccines better control COVID-19?Vaccine · 2021Review
- Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors.Nature communications · 2021Article
- Observational study on healthcare workers protection in the angiographic suite during the SARS-CoV-2 pandemic: before and during vax era.Journal of public health research · 2021Article
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
source citationVoysey M, Clemens SA, Madhi SA, et al.
Indexed as
Identifiers
33646835What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.